Abstract:Identifying and refining clinically significant patient stratification is a critical step toward realizing the promise of precision medicine in asthma. Several peripheral blood hallmarks, including total peripheral blood eosinophil count (BEC) and immunoglobulin E (IgE) levels, are routinely used in asthma clinical practice for endotype classification and predicting response to state-of-the-art targeted biologic drugs. However, these biomarkers appear ineffective in predicting treatment outcomes in some patients, and they differ in distribution between racially and ethnically diverse populations, potentially compromising medical care and hindering health equity due to biases in drug eligibility. Here, we propose constructing an unbiased patient stratification score based on DNA methylation (DNAm) and utilizing it to refine the efficacy of hallmark biomarkers for predicting drug response. We developed Phenotype Aware Component Analysis (PACA), a novel contrastive machine-learning method for learning combinations of DNAm sites reflecting biomedically meaningful patient stratifications. Leveraging whole-blood DNAm from Latino (discovery; n=1,016) and African American (replication; n=756) pediatric asthma case-control cohorts, we applied PACA to refine the prediction of bronchodilator response (BDR) to the short-acting β2-agonist albuterol, the most used drug to treat acute bronchospasm worldwide. While BEC and IgE correlate with BDR in the general patient population, our PACA-derived DNAm score renders these biomarkers predictive of drug response only in patients with high DNAm scores. BEC correlates with BDR in patients with upper-quartile DNAm scores (OR 1.12; 95% CI [1.04, 1.22]; P=7.9 e-4) but not in patients with lower-quartile scores (OR 1.05; 95% CI [0.95, 1.17]; P=0.21); and IgE correlates with BDR in above-median (OR for response 1.42; 95% CI [1.24, 1.63]; P=3.9e-7) but not in below-median patients (OR 1.05; 95% CI [0.92, 1.2]; P=0.57). These results hold within the commonly recognized type 2 (T2)-high asthma endotype but not in T2-low patients, suggesting that our DNAm score primarily represents an unknown variation of T2 asthma. Among T2-high patients with high DNAm scores, elevated BEC or IgE also corresponds to baseline clinical presentation that is known to benefit more from biologic treatment, including higher exacerbation scores, higher allergen sensitization, lower BMI, more recent oral corticosteroids prescription, and lower lung function. Our findings suggest that BEC and IgE, the traditional asthma biomarkers of T2-high asthma, are poor biomarkers for millions worldwide. Revisiting existing drug eligibility criteria relying on these biomarkers in asthma medical care may enhance precision and equity in treatment.

Personalized asthma management in pediatric patients based on treatment response

Precision care in the treatment of pediatric asthma

Critical evaluation of asthma biomarkers in clinical practice

Biomarkers in asthma, potential for therapeutic intervention

Biomarkers in asthma: state of the art

Utility of biomarkers in the diagnosis and monitoring of asthmatic children

Biomarkers and childhood asthma: improving control today and tomorrow

Toward personalization of asthma treatment according to trigger factors.

Recent developments and highlights in biomarkers in allergic diseases and asthma

From Biomarkers to Biologics

Airway molecular phenotypes in pediatric asthma

Asthma in the Precision Medicine Era: Biologics and Probiotics

Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma

Biologics in Asthma: A Molecular Perspective to Precision Medicine

Classification of Pediatric Asthma: From Phenotype Discovery to Clinical Practice

Epigenetic patient stratification via contrastive machine learning refines hallmark biomarkers in minoritized children with asthma

Recent advances in asthma biomarker research

A Roadmap for Using Causal Inference and Machine Learning to Personalize Asthma Medication Selection

Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes

Update on Inflammatory Biomarkers for Defining Asthma Phenotype

Controlling the Risk Domain in Pediatric Asthma through Personalized Care